Real-world data firm Litmus Health published its first census of wearable devices for clinical research.

The FIX-Padua therapy achieved FIX activity levels of 23% to 37%, suggesting it is several times more effective than unIQure's old asset.

The dermatology-focused Roivant subsidiary has hired Zavodnick to fill the role vacated by Jackie Fouse in September.

Cadent Therapeutics is coming out of stealth with a new CMO and $40 million to move its ion channel modulator programs into phase 2.

UB-312 prevented the accumulation of misfolded alpha-synuclein proteins in cell and animal models of Parkinson's disease.

Respiratory care specialist Vapotherm raised $56 million in an IPO on the New York Stock Exchange under the symbol VAPO.

Celgene is doubling down on its cancer immunotherapy pact with Dragonfly Therapeutics, paying $50 million for access to four more natural killer (NK) cell-…

Lilly is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug can clear headache pain in two hours.

Synthorx wants a $100 million IPO, but is the window closing?